CorMedix Inc. (CRMD) Stock Price & How to Invest

CorMedix is a New Jersey-based pharmaceutical company whose lead product, DefenCath (taurolidine and heparin), is the first and only FDA-approved antimicrobial catheter lock solution in the United States. It prevents catheter-related bloodstream infections in adult hemodialysis patients who use a central venous catheter, a population where infections drive costly hospitalizations and mortality, and a Phase III study showed up to a 71% reduction in infection risk. After a 2023 approval, commercialization scaled quickly through multi-year agreements that now cover roughly 60% of the U.S. outpatient dialysis market, and DefenCath generated about ~$167.6M in 2025 sales.

The investment picture shifted in 2025 when CorMedix acquired Melinta Therapeutics for ~$300M, adding six marketed infectious-disease products plus Toprol-XL and turning a single-product dialysis story into a broader institutional anti-infectives platform. The company is now solidly profitable and EBITDA-positive, with Q1 2026 revenue of ~$127.4M and net income of ~$38.6M, and it raised full-year 2026 guidance to ~$325M to $345M in revenue. The key debate is durability: how much of DefenCath's economics survive as early add-on reimbursement support (TDAPA) phases out, and whether Melinta and pipeline expansion can diversify away from heavy reliance on one drug.

Revenue is still heavily concentrated in DefenCath, so any adoption, contracting, or clinical setback would hit the whole story. The product benefited from early reimbursement support such as the Transitional Drug Add-On Payment (TDAPA), and those benefits are expiring, which could pressure pricing and margins as dialysis reimbursement normalizes. Competition is a latent threat: established players such as Amphastar could extend anticoagulant or lock-solution capabilities into the catheter-infection market. The Melinta portfolio carries integration risk and includes mature products with their own competitive and reimbursement dynamics. As a small-cap healthcare name, the shares are volatile and sensitive to policy, payer, and single-quarter execution swings.

5 analysts publish price targets on CRMD, averaging $15.40 against a $8.38 price as of September 2026, or +83.8%. The published targets run from $13.00 to $19.00, a moderate spread, and the ratings split 5 buy, 0 hold, 0 sell. Over the last six months there have been 3 raises and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full CRMD forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on CorMedix Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. DefenCath adoption in outpatient dialysis. DefenCath is the only FDA-approved antimicrobial catheter lock solution, and CorMedix has signed multi-year agreements reaching roughly 60% of the U.S. The most optimistic published target, $19.00, assumes this works close to its best case.

The case against. Revenue is still heavily concentrated in DefenCath, so any adoption, contracting, or clinical setback would hit the whole story. The most pessimistic target, $13.00, is roughly what CRMD is worth if this bites instead.

Read the full bull and bear case on CRMD, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see CorMedix Inc.'s investor relations page or your broker.

• Q1 2026 Revenue: ~$127.4M
• FY2026 Revenue Guidance: ~$325M-$345M
• Q1 2026 Net Income: ~$38.6M
• Q1 2026 Adjusted EBITDA: ~$70M
• Market Cap: ~$650M
• Analyst Avg Price Target: ~$14.5

CorMedix trades at a modest revenue multiple relative to many pre-profit biotech peers because it is already GAAP-profitable and EBITDA-positive, an unusual combination for a company only a couple of years into commercialization. Sell-side coverage skews constructive with an average 12-month target around ~$14.5, though price targets have drifted (for example RBC trimmed to ~$13 in mid-2026). The valuation debate centers on how durable DefenCath economics are once early reimbursement support fully rolls off.

Other names that sit close to CRMD: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get CRMD exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so CRMD sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where CRMD fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

CRMD is a rare profitable micro/small-cap pharma riding one breakout product, and the payoff hinges on DefenCath adoption holding up as its early reimbursement tailwind fades.

Whether CRMD is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is CRMD a buy or a sell?, and where the stock could go from here in the CRMD stock forecast.

For income investors, whether CRMD pays a dividend and how the payout looks is covered in does CRMD pay a dividend? And to weigh CRMD against a peer, read the full side-by-side comparisons: CRMD vs PFE and CRMD vs MRNA.